BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will participate in a panel at the 2024 BIO International Convention, taking place in San Diego, CA from June 3 – 6, 2024.

2024年5月20日，波士顿（环球通讯社）--专注于开发中枢神经系统（CNS）疾病精确新型疗法的Cerevance公司宣布，首席执行官克雷格·汤普森（CraigThompson）将参加2024年6月3日至6日在加利福尼亚州圣地亚哥举行的2024年生物国际大会的一个小组。

Details for the panel session are as follows: Title: Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision NeurotherapeuticsSession Date and Time: Tuesday, June 4 from 11 AM PT – 12 PM PT Location: San Diego Convention Center, Ballroom 26A About Cerevance Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis.

小组会议的细节如下：标题：针对大脑：生物技术如何揭示精确神经治疗的大脑疾病生物学会议日期和时间：6月4日星期二上午11点至下午12点PT地点：圣地亚哥会议中心，关于Cerevance的宴会厅26A Cerevance专注于开发中枢神经系统（CNS）疾病的精确治疗方法，包括阿尔茨海默氏病，帕金森氏病，额颞叶痴呆和肌萎缩性侧索硬化症等慢性神经退行性疾病。

Utilizing a large and growing repository of over 15,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states.

Cerevance利用超过15000个人脑组织样本的大型且不断增长的存储库，正在产生前所未有的表达水平和表观遗传数据，从而使公司能够确定下一代中枢神经系统疾病治疗的最有希望的目标。该公司使用其专有的核富集转录本排序测序（NetSeq）平台和先进的机器学习技术来揭示选定细胞类型的基因表达谱，以鉴定在受疾病影响的相关回路中独特表达或在疾病状态下改变的新靶点。

With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a fir.

凭借从研究中获得的信息，结合其科学家和药物开发团队的专业知识，Cerevance正在通过临床开发推进多种疗法，其中CVN424，CVN766和CVN293是最远的。CVN424是一个fir。